The US Food and Drug Administration has rejected a first-of-its-kind proposal to use the psychedelic drug MDMA, also known as ecstasy or Molly, as a treatment for post-traumatic stress disorder. Drugmaker Lykos Therapeutics had asked the FDA to approve the ...